Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently announced its decision to remove Novartis’ spinal muscular atrophy gene therapy onasemnogene abeparvovec from its accelerated assessment program.